Results 41 to 50 of about 15,937 (243)

Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study

BMC Pulmonary Medicine, 2017
Background No drugs have been approved for the treatment of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF), particularly those with idiopathic honeycomb lung.
Yosuke Tanaka, Mitsunori Hino, Akihiko Gemma   +2 more
doaj   +1 more source

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference [PDF]

, 2010
The response characteristics of the 6 minute walk test (6MWT) in studies of idiopathic pulmonary fibrosis (IPF) are only poorly understood, and the change in walk distance that constitutes the minimum important difference (MID) over time is ...
Behr, Jürgen, Brown, Kevin K., du Bois, Roland M., King, Talmadge E., Raghu, Ganesh, Swigris, Jeffrey J., Wamboldt, Frederick S.   +6 more
core   +1 more source

Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus-infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor

Infectious Disease Reports, 2015
Sildenafil and bosentan are increasingly used for the treatment of pulmonary arterial hypertension (PAH) in HIV-infected patients. However, concerns exist about pharmacokinetic interactions among sildenafil, bosentan and antiretroviral drugs, including ...
Pierangelo Chinello, Stefania Cicalini, Simona Pichini, Roberta Pacifici, Massimo Tempestilli, Maria P. Cicini, Leopoldo P. Pucillo, Nicola Petrosillo   +7 more
doaj   +1 more source

219. Tratamiento con bosentán en pacientes pre-fontan con presiones elevadas

Cirugía Cardiovascular, 2012
Evaluación inicial de los efectos del bosentán en el tratamiento de pacientes que van a ser sometidos a Fontan con presiones elevadas. Material y métodos: Presentamos una serie de ocho pacientes que recibieron bosentán previo a la derivación cavo ...
J. Otero, C. Merino, J. Casares, M. Conejero, D. Valencia, P. Maiorano, G. Sauchelli, I. Pernia, P. Alados, M.A. García, J. Moya, M. Román, I. Muñoz   +12 more
doaj   +1 more source

Under pressure: pulmonary hypertension associated with left heart disease. [PDF]

, 2015
© ERS 2015.Pulmonary hypertension (PH) associated with left heart disease (PH-LHD) is the most common type of PH, but its natural history is not well understood.
Farber, HW, Gibbs, S
core   +2 more sources

Bosentan Reduces Myocardial Ischemia-Reperfusion Injury in Rats

Kardiyovasküler Tıp E Dergisi/E Journal of Cardiovascular Medicine
Objectives: This study aimed to investigate the cardioprotective effects of bosentan, an endothelin receptor antagonist, against myocardial ischemia-reperfusion injury (MIRI) in rats.
Zeynep Yığman, Hüseyin Demirtaş, Mehmet Burak Gülcan, Abdullah Özer, Ali Doğan Dursun, Ayşegül Küçük, Mustafa Arslan   +6 more
doaj   +1 more source

Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. [PDF]

, 2014
The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascular (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was influenced by CV risk factors in PAH patients. We studied
Charalampopoulos, A, Connolly, SB, Davies, RJ, Gibbs, JS, Gin-Sing, W, Grapsa, J, Howard, LS, Nihoyannopoulos, P, Tzoulaki, I, Wilkins, MR   +9 more
core   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, Qing‐Wen Wang, James Cheng Chung Wei   +3 more
wiley   +1 more source

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. [PDF]

PLoS ONE, 2012
Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and ...
John Gatfield, Celia Mueller Grandjean, Thomas Sasse, Martine Clozel, Oliver Nayler   +4 more
doaj   +1 more source

Iontophoresis of endothelin receptor antagonists in rats and men. [PDF]

PLoS ONE, 2012
The treatment of scleroderma-related digital ulcers is challenging. The oral endothelin receptor antagonist (ERA) bosentan has been approved but it may induce liver toxicity.
Matthieu Roustit, Sophie Blaise, Claire Arnaud, Marcin Hellmann, Claire Millet, Diane Godin-Ribuot, Boris Dufournet, Jean Boutonnat, Christophe Ribuot, Jean-Luc Cracowski   +9 more
doaj   +1 more source